Drugs that are used in cancer therapy to erase epigenetic alterations in cancer cells simultaneously promote the production of countless mysterious gene transcripts, scientists from the German Cancer Research Center (DKFZ) now report in Nature Genetics. The substances activate hidden regulatory elements in DNA. The unusual gene activity has the potential to stimulate the immune system – a previously unnoticed effect that may increase the effect of therapeutic agents.
“This has been successfully done for years now in various cancers such as acute myeloid leukemia and myelodysplastic syndrome,” said Christoph Plass from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg. He added that it has also been proven that dangerous labels such as on tumor suppressor genes can be removed in this way. “However, the agents pass over the DNA like a lawn mower and remove practically all labels,” said Plass, who also serves as a research coordinator within the German Cancer Consortium (DKTK). “And so far nobody has studied in detail what effect this has on the tumor cells.”
Plass and his co-workers have now pursued this question in collaboration with colleagues from the U.S.A. Using genome-wide analyses, the scientists discovered that countless mysterious gene transcripts arise in the wake of treatment. This is due to an activation of specific regulatory elements in DNA, called promoters, which have been largely unnoticed so far. “There is total chaos in the treated cancer cells – we hadn’t expected that,” said David Brocks, who is one of the first authors of the study.
A closer look has shown that the activated regulatory elements originate from viruses that inserted themselves into the genome in the ancient past. However, they were turned off in the course of evolution, thus becoming normal components of DNA.
Protein fragments that form on the basis of these peculiar gene transcripts have the potential to be recognized by the immune system and, thus, to stimulate the immune system. This might increase the effectiveness of drugs that are being used. “Now we have to investigate whether this effect can be used specifically to improve therapy,” Plass said. And yet another aspect: “These gene transcripts might be useful as biomarkers to examine whether an epigenetic therapy is effective and reasonable in the individual patient.”
David Brocks, Christopher R. Schmidt, Michael Daskalakis, Hyo Sik Jang, Nakul M. Shah,Daofeng Li, Jing Li, Bo Zhang, Yiran Hou, Sara Laudato, Daniel B. Lipka, Johanna Schott, Holger Bierhoff, Yassen Assenov, Monika Helf, Alzbeta Ressnerova, Md Saiful Islam, Anders M. Lindroth, Simon Haas, Marieke Essers, Charles D. Imbusch, Benedikt Brors, Ina Oehme, Olaf Witt, Michael Lübbert, Jan-Philipp Mallm, Karsten Rippe, Rainer Will, Dieter Weichenhan, Georg Stoecklin, Clarissa Gerhäuser, Christopher C. Oakes, Ting Wang, und Christoph Plass: DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nature Genetics, 2017, DOI: 10.1038/ng.3889
An image for this press release is available at:
Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: Schuster, DKFZ”.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: firstname.lastname@example.org). Any commercial use is prohibited.
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.